Lisata Therapeutics

433 articles about Lisata Therapeutics

• Caladrius Biosciences to Present at the BIO CEO & Investor Conference

  2/8/2022

  Caladrius Biosciences, Inc. announced that David J. Mazzo, PhD, President and CEO of Caladrius, will be presenting a corporate overview at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.

• Caladrius Biosciences Announces Participation in Upcoming Conferences in January 2022

  1/4/2022

  Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, announced its participation in several industry and investor events.

• Caladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial Results

  11/4/2021

  Caladrius Biosciences, Inc. provides a corporate update and reports financial results for the three and nine months ended September 30, 2021.

• Caladrius Biosciences to Host Third Quarter 2021 Financial Results Conference Call on Thursday, November 4th at 4:30 p.m. Eastern Time

  10/28/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended September 30, 2021, on Thursday, November 4, 2021, at 4:30 p.m. (ET).

• Caladrius Biosciences Announces Participation in Upcoming Conferences in October 2021

  10/4/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events.

• Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/8/2021

  Caladrius Biosciences, Inc. announced that David J. Mazzo, PhD, President and CEO of Caladrius, will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.

• 

  BioSpace Movers & Shakers: Sept. 3

  9/3/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D., as Chief Medical Officer

  9/1/2021

  Caladrius Biosciences, Inc. today announced the appointment of Dr. Kristen K. Buck as the Company’s Chief Medical Officer (“CMO”).

• Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business UpdateConference call begins today at 4:30 p.m. Eastern Time

  8/5/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results for the three and six months ended June 30, 2021.

• Caladrius Biosciences to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:30 p.m. Eastern Time

  7/29/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended June 30, 2021, on Thursday, August 5, 2021, at 4:30 p.m. (ET).

• Caladrius Biosciences to Present at Zooming with LD

  7/22/2021

  Caladrius Biosciences, Inc. today announced that its President and CEO, David J. Mazzo, PhD, will be presenting virtually at the Zooming with LD event on Thursday, July 29, 2021, at 10:00am Pacific Time/1:00pm Eastern Time.

• Caladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney DiseaseFDA authorizes new IND for the study of CLBS201 in patients with reduced kidney function

  6/22/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), today announced that the U.S. Food and Drug Administration (“FDA”) has authorized its investigational new drug (“IND”) application for the study of CLBS201, a CD34+ cell therapy for the treatment of diabetic kidney disease (“DKD”).

• Caladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit

  6/17/2021

  Caladrius Biosciences, Inc. today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius, will present at the Investor Forum at the World Stem Cell Summit to be held (virtually) June 14-18, 2021.

• Caladrius Biosciences Announces Participation in Upcoming Conferences in June 2021

  6/1/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events: NCVH Annual Conference (June 1-4, 2021)

• Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in May 2021

  5/4/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events:

• Caladrius Biosciences to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time

  4/29/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended March 31, 2021 on Thursday, May 6, 2021 at 4:30 p.m. (ET).

• Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease

  3/8/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to the Company’s CD34+ cell therapy product, CLBS12, for the treatment of Buerger’s disease

• Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

  3/3/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021.

• Caladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time

  2/18/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three and twelve months ended December 31, 2020 on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time

• Caladrius Biosciences, Inc. Closes $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules

  2/17/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has closed on its previously announced sale to institutional investors of an aggregate of 24,906,134 shares of its common stock and warrants to purchase up to an aggregate of 12,453,067 shares of common stock